Consensus on precision medicine for metastatic cancers: a report from the MAP conference

C Swanton; J-C Soria; A Bardelli; A Biankin; C Caldas; S Chandarlapaty; L de Koning; C Dive; J Feunteun; S-Y Leung; R Marais; E R Mardis; N McGranahan; G Middleton; S A Quezada; J Rodón; N Rosenfeld; C Sotiriou; F André

doi:10.1093/annonc/mdw192

Consensus on precision medicine for metastatic cancers: a report from the MAP conference

C Swanton, J-C Soria, A Bardelli, A Biankin, C Caldas, S Chandarlapaty, L de Koning, C Dive, J Feunteun, S-Y Leung, R Marais, E R Mardis, N McGranahan, G Middleton, S A Quezada, J Rodón, N Rosenfeld, C Sotiriou, F André

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

61 Citations (Scopus)

Abstract

Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation sequencing of tumors and ddPCR on circulating free DNA have convincing analytical validity. Further work needs to be undertaken to establish the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that precision medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.

Original language	English
Pages (from-to)	1443-1448
Number of pages	6
Journal	Annals of Oncology
Volume	27
Issue number	8
Early online date	3 May 2016
DOIs	https://doi.org/10.1093/annonc/mdw192
Publication status	Published - Aug 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdw192Licence: None: All rights reserved

Cite this

Swanton, C., Soria, J-C., Bardelli, A., Biankin, A., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S-Y., Marais, R., Mardis, E. R., McGranahan, N., Middleton, G., Quezada, S. A., Rodón, J., Rosenfeld, N., Sotiriou, C., & André, F. (2016). Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Annals of Oncology, 27(8), 1443-1448. Advance online publication. https://doi.org/10.1093/annonc/mdw192

@article{5c0d2e3fc5a84ba8ba71c3b7692a6d05,

title = "Consensus on precision medicine for metastatic cancers: a report from the MAP conference",

abstract = "Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation sequencing of tumors and ddPCR on circulating free DNA have convincing analytical validity. Further work needs to be undertaken to establish the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that precision medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.",

author = "C Swanton and J-C Soria and A Bardelli and A Biankin and C Caldas and S Chandarlapaty and {de Koning}, L and C Dive and J Feunteun and S-Y Leung and R Marais and Mardis, {E R} and N McGranahan and G Middleton and Quezada, {S A} and J Rod{\'o}n and N Rosenfeld and C Sotiriou and F Andr{\'e}",

note = "{\textcopyright} The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",

year = "2016",

month = aug,

doi = "10.1093/annonc/mdw192",

language = "English",

volume = "27",

pages = "1443--1448",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "8",

}

Swanton, C, Soria, J-C, Bardelli, A, Biankin, A, Caldas, C, Chandarlapaty, S, de Koning, L, Dive, C, Feunteun, J, Leung, S-Y, Marais, R, Mardis, ER, McGranahan, N, Middleton, G, Quezada, SA, Rodón, J, Rosenfeld, N, Sotiriou, C & André, F 2016, 'Consensus on precision medicine for metastatic cancers: a report from the MAP conference', Annals of Oncology, vol. 27, no. 8, pp. 1443-1448. https://doi.org/10.1093/annonc/mdw192

TY - JOUR

T1 - Consensus on precision medicine for metastatic cancers

T2 - a report from the MAP conference

AU - Swanton, C

AU - Soria, J-C

AU - Bardelli, A

AU - Biankin, A

AU - Caldas, C

AU - Chandarlapaty, S

AU - de Koning, L

AU - Dive, C

AU - Feunteun, J

AU - Leung, S-Y

AU - Marais, R

AU - Mardis, E R

AU - McGranahan, N

AU - Middleton, G

AU - Quezada, S A

AU - Rodón, J

AU - Rosenfeld, N

AU - Sotiriou, C

AU - André, F

PY - 2016/8

Y1 - 2016/8

N2 - Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation sequencing of tumors and ddPCR on circulating free DNA have convincing analytical validity. Further work needs to be undertaken to establish the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that precision medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.

AB - Recent advances in biotechnologies have led to the development of multiplex genomic and proteomic analyses for clinical use. Nevertheless, guidelines are currently lacking to determine which molecular assays should be implemented in metastatic cancers. The first MAP conference was dedicated to exploring the use of genomics to better select therapies in the treatment of metastatic cancers. Sixteen consensus items were covered. There was a consensus that new technologies like next-generation sequencing of tumors and ddPCR on circulating free DNA have convincing analytical validity. Further work needs to be undertaken to establish the clinical utility of liquid biopsies and the added clinical value of expanding from individual gene tests into large gene panels. Experts agreed that standardized bioinformatics methods for biological interpretation of genomic data are needed and that precision medicine trials should be stratified based on the level of evidence available for the genomic alterations identified.

U2 - 10.1093/annonc/mdw192

DO - 10.1093/annonc/mdw192

M3 - Article

C2 - 27143638

SN - 0923-7534

VL - 27

SP - 1443

EP - 1448

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Consensus on precision medicine for metastatic cancers: a report from the MAP conference

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this